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Abstract 
Rheumatoid Arthritis is a systemic disease characterized by massive joint destruction and deformity. The disease 
leads to increased morbidity and mortality especially if associated with other diseases like Metabolic Syndrome. 
Metabolic syndrome is a cluster of risk factors caused by abdominal obesity, such as hyperglycemia, 
hypertension, dyslipidemia, and insulin resistance. Rheumatoid arthritis has been found to be associated with 
metabolic syndrome. The present paper aims to assess the correlation between metabolic syndrome and different 
treatment modalities like steroids or methotrexate that are used to treat Iraqi patients with Rheumatoid Arthritis. 
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1. Introduction 
1.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, joint tenderness, 
and destruction of synovial joints, leading to severe disability and premature mortality (Wolfe 1996). Given the 
presence of autoantibodies, such as rheumatoid factor (RF) and anti–citrullinated protein antibody (ACPA), 
which can precede the clinical manifestation of RA by many years (Nielen et al.2004), RA is considered an 
autoimmune disease; autoimmunity and the overall systemic and articular inflammatory load drive the 
destructive progression of the disease (Firestein 2003). Joint damage is rarely apparent in the very early stages of 
disease, but rather accumulates consistently over time (Machold 2002). 
Over the last decade, the optimal use of disease-modifying antirheumatic drugs (DMARDs), in 
particular the anchor DMARD methotrexate (MTX) (Visser et al. 2009), and the availability of new biologic 
agents (Smolen et al. 2007; Doan & Massarotti 2005), have dramatically enhanced the success of RA 
management. Moreover, it has been recognized that early therapeutic intervention improves clinical outcomes 
and reduces the accrual of joint damage and disability (Bukhari et al. 2003; Van Dongen et al. 2007). 
 
1.2 Metabolic syndrome  
Metabolic syndrome (MetS) is a constellation of interrelated risk factors of metabolic origin (Sattar et al. 2003). 
The features of MetS include: Central obesity, Insulin resistance, dyslipidemia, high blood pressure, 
prothrombotic state, and proinflammatory state (Wang et al. 2007). 
The appropriate way to define MetS is still under debate, Several groups including the world health 
organization (WHO) (Alberti and Zimmet 1998), The National Cholesterol Education Program Adult Treatment 
Panel ІІІ (NCEP ATPІІІ) (Third Report of the NCEP ATPІІІ 2002), and the International Diabetes Federation 
(IDF) (The IDF consensus worldwide definition of metabolic syndrome 2005) have proposed criteria to define 
this syndrome for research purpose or early clinical identification.  In 2001, the (NCEP ATP III) simplified the 
WHO criteria by requiring three of five simple clinical measures, increased waist circumference (WC), elevated 
triglycerides (TG), reduced high density lipoprotein cholesterol (HDL-C), elevated blood pressure (Bp), and 
elevated plasma glucose. The various MetS definitions include the same core criteria: obesity, insulin resistance, 
dyslipidemia and hypertention, but differ in the cut-off points for individual criteria and in the inclusion of 
additional factors (eg. microalbuminuria). The WHO, for instance, requires evidence of insulin resistance or DM 
to make a diagnosis of MetS, while the IDF requires a certain degree of abdominal obesity. The NCEP, however, 
considers the five components equal in importance (Reaven 2006). According to Scott Grundy, University of 
Texas Southwestern Medical School, Dallas, Texas, the intent was just to update the NCEP ATP III definition 
and not create a new definition (Grundy et al. 2004). These include the following: 
1. increase waist circumference:  
• Men — Equal to or greater than 40 inches (102 cm) 
• Women — Equal to or greater than 35 inches (88 cm) 
2. Elevated triglycerides: Equal to or greater than 150 mg/dL (1.7 mmol/L) 
3. Reduced HDL (“good”) cholesterol:  
• Men — Less than 40 mg/dL (1.03 mmol/L) 
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• Women — Less than 50 mg/dL (1.29 mmol/L) 
4. Elevated blood pressure: Equal to or greater than 130/85 mm Hg or use of medication for hypertension 
5. Elevated fasting glucose: Equal to or greater than 100 mg/dL (5.6 mmol/L) or use of medication for 
hyperglycemia 
 
2. Material & Methods 
2.1 Study population 
A total number of 203 patients with RA meeting the American College of Rheumatology Criteria for the 
classification of rheumatoid arthritis participated in the study.  The patients attended the Rheumatology & 
Rehabilitation Department of Baghdad Teaching Hospital during 2010. All patients gave their informed written 
consents prior to commencement of the study. 
 
2.2 Assessment of the metabolic syndrome
 
The metabolic syndrome was diagnosed according to NCEP III criteria (Third Report of the NCEP ATPІІІ 2002). 
All participants had an extensive baseline assessment including a detailed record of their medical history, 
physical examination, and measurements of basic demographics: (age, gender, height, weight, body mass index 
(BMI), waist circumference and smoking status). 
 
2.3 Laboratory tests 
Baseline blood samples were obtained from each patient and were analyzed in the same laboratory. Blood 
samples were taken in the morning after 10 hours of overnight fasting. Blood tests included: C reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), fasting lipid profile: [total cholesterol (TC), high density 
lipoprotein (HDL), low density lipoproteins (LDL) and triglycerides (TG)], rheumatoid factor, liver function 
tests, renal function tests, and fasting glucose. 
 
2.4 Rheumatoid arthritis disease characteristics 
Patients' data were obtained via case note analysis and a face - to- face interview performed by rheumatologist.  
Rheumatoid arthritis disease-related data, such as disease duration, extra-articular manifestations (as a marker of 
disease severity), physical activity and drug use (all anti-rheumatic drugs and glucocorticoid use), were recorded. 
 
3. Results 
3.1 Descriptive characteristics of study population 
Among the 203 patients with RA, 162 (79.8%) were women and 41 (20.2%) were men, with a mean (SD) age of 
46.9±11.5 years. No significant differences between the mean age of men than that of women among patients 
with RA (48.0±12.6 versus 46.6±11.3 p=0.507). 
 
3.2 Prevalence of MetS
 
The prevalence of MetS was 51.2% in study subjects being 29.3% in male and 56.8% in female. When the 
prevalence of MetS was analyzed in various age groups, there was no significant difference between male and 
female prevalence in any specific age group while a significant difference was depicted comparing the total 
number (p=0.046) as shown in table 1. 
 
3.3 Correlations 
The study found a significant correlation between age and BMI (p<0.001) along with number of metabolic 
syndrome components in RA patients (p<0.001). Also a significant positive correlation was found between 
duration of RA disease and the number of criteria related to metabolic syndrome (p<0.05). 
 
3.4 Therapy and MetS 
Regarding the possible association between treatment factors and MetS in RA patients; table 2 shows that the 
usage of steroid dose ≥ 10mg for more than 3 months duration were more common in patients with MetS (p 
˂0.001), similarly the MetS tend to be more common in patients that don't take or on irregular uses of 
methotrexate (p=0.032). Biological treatment did not seem to have an effect on MetS in this study (p=0.532). 
 
4. Discussion 
This study reported a high prevalence of MetS among Iraqi rheumatoid patients according to the NCEP 2001, as 
agreed by previous studies (Chung et al. 2007; Karvounaris et al. 2007). This prevalence was significantly 
higher in women than in men which differ from previous studies on the prevalence of MetS done by Chung et al
 
(2007), Karvounaris et al
 
(2007),
 
and Toms et al
 
(2009) who showed
 
the same prevalence rate between men and 
women. 
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This study showed a linear correlation between high BMI and age; which agrees with previous studies 
(Dessein et al. 2002; Chung et al. 2007; Chung et al. 2008). The economic growth of the Gulf region has 
resulted in increases in health problems and related diseases especially obesity in Asian population. This was 
first noted in developed states (Pischon et al. 2008), but has rapidly spread to third world countries in the past 
few years (Chung et al. 2008; WHO Expert Committee). The hot climates and sand storms largely discourage 
outdoor activities while indoor activities (such as TV watching) and socializing frequently involve eating and 
snacking; subsequently resulting in obesity (Chung et al. 2008).
 
This study found a significant relation between RA and the number of components of MetS in 
agreement with a study done in Brazil (Da Cunha et al. 2012) and the QUEST-RA Study (Sokka et al. 2009). 
Moreover, in a multivariate model assessment, the risk of having severe relapses was found to be significantly 
higher for patients with MetS compared to those without MetS even after further adjusting for RA treatments, 
demographics and behavioral factors. 
The present data suggested that RA disease duration correlates posatively with MetS, implicating a 
significant role for the inflammatory burden in the evolution of metabolic disturbances in patients with RA. This 
finding is in agreement with the study done by Karvounaris et al
 
(2007). 
The results concerning treatment agents and MetS showed lack of significant association between 
glucocorticoid use at any dose and the presence of MetS but when the dose increased to ≥10mg/day for more 
than 3 months duration there was a significant increase in the risk of development of MetS; this result in part 
differ from data presented by Toms et al. (2008) which may be due to effects of other drugs such as biological 
agents in that study leaving little scope for additive effects of glucocorticoid. The present study also 
demonstrated that patients on regular doses of methotrexate were less likely to developed MetS than those who 
don't take or on irregular uses of the drug; this finding is in agreement to previous studies (Zonana-Nacach et al. 
2008; Toms et al
 
2009).  About 2% of patients in this study were on biological treatment while the study done by 
Karvounaris et al
 
(2007) reported 40% taking anti-TNFα agents
 
this may be due to the limited availability of 
these drugs in our hospital. 
 
5. Conclusion 
This paper confirms a positive correlation between metabolic syndrome components and duration of rheumatoid 
arthritis. Chronic inflammatory state of metabolic syndrome may be correlated to treatment by high doses of 
steroids or irregular uses of methotrexate in Rheumatoid arthritis patients. 
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Table 1. Prevalence of the Metabolic Syndrome in patients with Rheumatoid Arthritis 
 Metabolic Syndrome 
Age Group (years) 
Women  Men  Total  
N (%) N (%) N (%) P 
*
 
< 40 46/105 (43.8) 6/25 (24.0) 52/130 (40.0) 0.101 
40 – 59 29/40 (72.5) 2/10 (20.0) 31/50 (62.0) 0.791 
≥60 17/17 (100.0) 4/6 (66.7) 21/23 (91.3) 0.064 
Total 92/162 (56.8) 12/41 (29.3) 104/203 (51.2) 0.046 
*Significant P values (< 0.05) are highlighted in bold. 
 
Table 2. Association between Treatment factors and Metabolic Syndrome in patients with Rheumatoid 
Arthritis. 
Variables 
Women with RA Men with RA All with RA 
MetS + MetS- P
 *
 MetS + MetS- P
 *
 MetS + MetS- P
 *
 
(n=92;%) (n=70;%) (n=12;%) (n=29;%) (n=104;%) (n=99;%) 
Steroids; any dose;, n (%) 
take 51(56.7) 31(44.3) 
0.120 
5(45.5) 14(48.3) 
0.873 
56(55.4) 45(45.5) 
0.158 
Not take 39(43.3) 39(55.7) 6(54.5) 15(51.7) 45(44.6) 54(54.5) 
Steroid dose (mg/day), > 3 months; n (%) 
≥10 36(81.8) 13(43.3) 
0.001 
1(50.0) 5(38.5) 
1.000 
37(80.4) 18(41.9) 
0.000 
< 10 8(18.2) 17(56.7) 1(50.0) 8(61.5) 9(19.6) 25(58.1) 
Methotrexate: Under Treatment; n (%) 
Irregular/ 
Not used 
57(63.3) 34(48.6) 
0.061 
6(66.7) 14(48.3) 
0.454 
63(63.6) 48(48.5) 
0.032 
Regular 
use 
33(36.7) 36(51.4) 3(33.3) 15(51.7) 36 (36.4) 51(51.5) 
Biologic agents; n (%) 
take 1(1.1) 1(1.4) 
1.000 
0(0.0) 1(3.4) 
0.515 
1(1.0) 2(2.0) 
0.532 
Not take 91(98.9) 69(98.6) 12(100.0) 28(96.9) 103(99.0) 97(98.0) 
RF, rheumatoid factor; MetS+, metabolic syndrome; MetS-, no metabolic syndrome; RA, rheumatoid arthritis. 
*Difference between patients with RA with and without MetS. 
 Significant P values (< 0.05) are highlighted in bold. 
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